This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

Gold, incentives and meh

Detect: Detection and diagnosis

This guide details how to diagnose AF using an ECG.



Protect: Anticoagulants available for your patients

The properties of NOACs may make them preferable to VKA for most eligible and appropriate NVAF patients, for example those who would struggle to attend regular clinic visits or who already take several concomitant medications. Find out more through these case studies.



Perfect: Improving anticoagulation services

The following patient leaflet is available to support you in helping your patients to understand more about their condition, treatment options and beyond:

Case studies – assessment of anticoagulation

These case studies highlight typical scenarios that may arise during assessment of anticoagulation.

ELIQUIS (apixaban)

Additional benefits

To support you in assessing your patients’ suitability prior to initiating treatment with ELIQUIS, a Prescriber Checklist is available here.

For patients who are switching from warfarin to ELIQUIS, a Patient Information Leaflet is available here.

Click here to view ELIQUIS (apixaban) prescribing and adverse event reporting information.

YOU ARE ABOUT TO LEAVE THIS WEBSITE.

×

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

YOU ARE ABOUT TO LEAVE THIS WEBSITE.

×

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

YOU ARE ABOUT TO LEAVE THIS WEBSITE.

×

This link takes you to a third party website (outside of the Bristol-Myers Squibb Group and Pfizer Group). Bristol-Myers Squibb and Pfizer has no control over the content or management of third party websites nor can it be held responsible or liable for such content or management. Please make sure the contents therein are suitable for you as per its intended audience and the applicable laws and regulations. It is recommended that you carefully read the legal notice and cookies and privacy policy of third party websites before accessing these sites.

If you wish to continue, click ‘Continue’, otherwise click ‘Stay on this site’.

Continue Stay on this site

Job code: 432UK1900440-01
Date of preparation: September 2019

Pfizer BMS logo